Join the Ovarian Cancer group to help and get support from people like you.
Ovarian Cancer News (Page 2)
Related terms: Cancer, Ovarian, Cancer, Ovaries
Common Genetic Risk Seen for Primary Ovarian Insufficiency, Cancer
WEDNESDAY, July 31, 2024 – There seems to be a common genetic risk for primary ovarian insufficiency (POI) and reproductive cancer risk, according to a study published online July 12 in the Journal...
Risk for Ovarian Cancer Increased for Women With Endometriosis
THURSDAY, July 18, 2024 – Women with endometriosis have an increased risk of ovarian cancer, with the highest risk seen for women with deep infiltrating endometriosis and/or ovarian endometriomas,...
Endometriosis Linked to Four-fold Higher Odds for Ovarian Cancer
THURSDAY, July 18, 2024 – Women who struggle with endometriosis may be vulnerable to another health danger: New research shows they are about four times more likely to develop ovarian cancer than...
Premenopausal Bilateral Oophorectomy Before Age 40 Affects Brain White Matter
TUESDAY, July 9, 2024 – Women who undergo premenopausal bilateral oophorectomy (PBO) before age 40 years have reduced brain white matter integrity in later life, according to a study published...
FDA Approves Tepylute (thiotepa) Ready-to-Dilute Injectable Formulation to Treat Breast Cancer and Ovarian Cancer
CAMBRIDGE, Mass.--(BUSINESS WIRE) June 28, 2024 --Shorla Oncology (‘Shorla’), a U.S.-Ireland specialty pharmaceutical company, announced today that the U.S. Food and Drug Administration (FDA) has app...
J&J Settles Talcum Powder Lawsuits From States for $700 Million
THURSDAY, June 13, 2024 – Johnson & Johnson will pay $700 million to settle claims from 42 states and the District of Columbia that the company continued to market its talcum powder products even as...
ENDO: Early Menopause Tied to Heightened Risk for Breast, Ovarian Cancer
TUESDAY, June 11, 2024 – Women with early menopause have a two times greater risk for breast cancer and a nearly four times higher risk for ovarian cancer, according to a study presented at the...
Very Early Menopause Could Raise Odds for Breast, Ovarian Cancers
TUESDAY, June 4, 2024 – Menopause before the age of 40 could raise a woman's long-term risk for breast or ovarian cancers, new research suggests. Besides that, "there is also higher risk of breast,...
ASCO: Conjugated Equine Estrogen May Increase Risk for Ovarian Cancer
TUESDAY, May 28, 2024 – Conjugated equine estrogen (CEE) taken alone for menopause may increase the risk for developing and dying from ovarian cancer, according to a study presented at the annual...
Genital Talc Use Positively Linked to Ovarian Cancer
TUESDAY, May 21, 2024 – There is a positive association between use of intimate care products, including genital talc, and ovarian cancer, according to a study published online May 15 in the Journal...
Johnson & Johnson Will Pay $6.5 Billion to Settle Talc Ovarian Cancer Lawsuits
THURSDAY, May 2, 2024 – Johnson & Johnson announced Wednesday that it would pay out more than $6.5 billion over the next 25 years to settle existing lawsuits claiming that its talc-containing...
U.S. Food and Drug Administration (FDA) Grants Full Approval for Elahere (mirvetuximab soravtansine-gynx) for Certain Ovarian Cancer Patients
The full approval of Elahere is based on the confirmatory MIRASOL Phase 3 trial that supports the medicine as a potential new standard of care for folate receptor alpha (FRα)-positive, ...
FDA Approves Elahere (mirvetuximab soravtansine-gynx) for the Treatment of Platinum-Resistant Ovarian Cancer
Elahere is the First ADC Approved by FDA for Platinum-Resistant Ovarian Cancer Indication Covers Patients with One to Three Prior Systemic Treatment Regimens, Regardless of Prior Avastin® Use ...
FDA Approves Vegzelma (bevacizumab-adcd), a Biosimilar to Avastin
Vegzelma is Celltrion’s third oncology biosimilar to receive approval from the U.S. FDA Vegzelma offers U.S. patients living with multiple types of cancer a new, safe, and effective treatment option ...
FDA Approves Alymsys (bevacizumab-maly), a Biosimilar to Avastin
BRIDGEWATER, N.J.--(BUSINESS WIRE) April 13, 2022 --Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced that the U.S. Food and Drug Administration (FDA) has approved ...